Genetic Markers Indicate that 1,25-dihydroxyvitamin D Treatment may not Protect Against Hepatocellular Carcinoma


ÖNER Ç., ÇOLAK E.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.5, no.2, pp.117-122, 2021 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.14744/ejmo.2021.65874
  • Journal Name: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.117-122
  • Keywords: 1.25-Dihydroxyvitamin D, hepatocellular carcinoma, motility, PIWI interacting RNA, proliferation, VITAMIN-D, IN-VITRO, CELL-CYCLE, CANCER, INHIBITION, PATHWAY, GROWTH, TUMORIGENESIS, ANGIOGENESIS, CONTRIBUTES
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objectives: The impact of 1,25-dihydroxyvitamin D on hepatocellular carcinoma (HCC) cells is a complicated area. In this study, we aimed to clarify the effect of 1,25-dihydroxyvitamin D on HCC cells according to genetic markers.